Summary
The master protocol study J2N-MC-JZNY provides a framework to enable the evaluation of
the long-term safety and efficacy of pirtobrutinib after completion of clinical studies
evaluating pirtobrutinib. The clinical studies that will feed into this master protocol
are referred to as originator studies. The master protocol will govern individual
study-specific appendices (ISAs) that will represent participants from the individual,
completed originator studies. These participants will have the opportunity to enter this
study and continue to receive treatment or continue follow-up visits. Overall, the master
protocol and the individual ISAs, when combined, define the investigations for this
study.